Compare Southwest Airlines Co (LUV) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Novartis AG — how do they compare? Southwest Airlines Co trades at $41.21 (market cap $20.23B), while Novartis AG trades at $143.23 (market cap $268.57B). The key difference: Novartis AG is far larger — about 13.3× Southwest Airlines Co's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 65 Days and Novartis AG for 82 Days on average.
| LUV | NVS | |
|---|---|---|
Market Cap | $20.23B | $268.57B |
Volume | 14,560,422 | 1,532,573 |
Sector | Industrials | Health |
52-Week High | $54.80 | $168.62 |
52-Week Low | $29.67 | $121.80 |
Typical Hold Time | 65 Days | 82 Days |
Enterprise Value | $23.33B | $309.89B |
Dividend Yield | 1.74% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $41.15, down 1.37% on the day, amid a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a P/E of 25.85 and net income margin of 2.78%, while cash flow trends indicate a projected recovery in 2026. Recent news highlights the company's commercial transformation initiatives, including new fare structures and lounge plans, aiming to boost profitability.
Outlook remains cautiously optimistic with a consensus price target of $49.61, suggesting upside potential, though risks include volatile fuel costs and competitive pressures. The stock's valuation appears reasonable relative to sales, but investors should weigh near-term operational headwinds against long-term strategic gains.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
